Clinical Trial Update: A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating AB-1001 Striatal Administration for Huntington's disease is ongoing but not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• AB-1001

Snippet

Sponsor: Brainvectis, a subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio) | Conditions: Huntington Disease | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING